The company has appointed Scott Coiante as Senior Vice President and Chief Financial Officer.
An experienced finance executive in biotech, Mr. Coiante brings nearly 20 years of accounting, fundraising and operational experience to Aprea.
“Aprea is leading the way in developing small molecule reactivators of mutant p53 and, in addition to its growing clinical pipeline, is advancing rapidly in a Phase 3 clinical trial in MDS. I look forward to working with the management team to establish a financial infrastructure that will further the company’s success,” said Mr Coiante.
Experienced finance executive
Scott Coiante joins Aprea from Agile Therapeutics, where he was Senior Vice President and Chief Financial Officer. Having served at Agile since 2010, he played a leadership role in the company and in the development of the internal finance and accounting infrastructure. Prior to joining Agile, he was from 2002 Vice President of Finance and Treasurer at Medarex, Inc., formerly a NASDAQ listed biotech company that was acquired in 2009 by Bristol Myers Squibb. Mr. Coiante received a BS in Accounting from Villanova University.
“We are thrilled to welcome Scott to the Aprea team,” said Christian S. Schade, President and Chief Executive Officer of Aprea Therapeutics. “His many years of finance leadership and company building complement Aprea’s determined strategy to advance novel oncology therapies.”
